Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis

BACKGROUND: No evidence of disease activity (NEDA) is a composite measurement, incorporating clinical and magnetic resonance imaging (MRI) elements of disease activity to sensitively evaluate the therapeutic efficacy of treatments for relapsing–remitting multiple sclerosis (RRMS). OBJECTIVE: To asse...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnold, Douglas L., Shang, Shulian, Dong, Qunming, Meergans, Matthias, Naylor, Maria L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113732/
https://www.ncbi.nlm.nih.gov/pubmed/30181780
http://dx.doi.org/10.1177/1756286418795085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113732/
https://www.ncbi.nlm.nih.gov/pubmed/30181780
http://dx.doi.org/10.1177/1756286418795085

Ejemplares similares